Merck launches Pergoveris Pen for Infertility treatment in India

Infertility is no less than an endemic for Indians and is vastly dependent on a proper ovulation cycl

105
Medical Devices Lab

Last Updated on August 11, 2021 by The Health Master

Merck Specialties Pvt ltd, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India.

This launch emphasizes the company’s motive of fulfilling unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency.

The novel first-hand version of the Pergoveris Pen is a breakthrough combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment.

In addition, by eliminating the need for mixing, Pergoveris Pen is the world’s first combined therapy option for recombinant gonadotropins, demonstrating the efficacy, safety, and combinability of recombinant follitropin alfa with recombinant lutropin alfa, in a single ready to inject device, using Filled-By-Mass Technology, for infertile women in a physiological ratio of 2:1.

Infertility is no less than an endemic for Indians and is vastly dependent on a proper ovulation cycle. Ovulation is a process whereby a mature, fertilizable oocyte is released from the ovarian follicle. This process is the result of a well-defined sequence of events that includes the combined effect of the pituitary gonadotropins, FSH, and LH.

Any functional disorder of the hypothalamic-pituitary-ovarian axis may lead to the absence of or infrequent ovulation, resulting in infertility. The new Pergoveris Pen allows an improved treatment experience for patients with severe FSH and LH deficiency upon prescription by an IVF specialist.

“As multiple studies suggest that nearly 27.5 million Indian couples deal with infertility and are actively seeking fertility solutions, we strive to fulfill dreams of such couples aspiring to become parents, by providing them with advanced treatment options.

Our commitment to delivering an optimal range of products in the field of fertility medicines is a step forward with the latest addition of Pergoveris ready-to-use Pen, being an only premixed combination of recombinant human FSH (rhFSH) and recombinant human LH (rhLH) in the Indian markets” said Anandram Narasimhan, managing director, Merck Specialities Pvt Ltd.”

Alkem launches Ibuprofen, Famotidine tablets

Zydus Cadila gets final nod from USFDA for Fulvestrant injection

USFDA inspection ends with ‘Zero’ observations: Alkem

Granules Pharma clears USFDA audit

Zydus Cadila gets USFDA nod for Ibrutinib tablets

Lupin gets USFDA nod for generic Antifungal drug

Latest Notifications regarding Pharmaceuticals

Mix of Covishield, Covaxin yields better results: ICMR Study

Covaxin: Over 200 quality control tests: claims Bharat Biotech

This is major side effect of rampant use of Steroids

Govt increases Jan Aushadhi Store incentive up to Rs 5 lakhs

Covishield, Covaxin monthly production increase upto 120 million doses

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner